Sugi Predict

Sugi Predict / Compounds / SCHEMBL3208224

SCHEMBL3208224

SCHEMBL3208224

CC(C(=O)c1c(-c2ccc(F)cc2)nn2ccccc12)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.44
▸ EGFR P00533 3/20 0.44
▸ ADORA2A P29274 2/20 0.44
▸ ADORA1 P30542 2/20 0.44
▸ RAF1 P04049 1/20 0.44
▸ ADORA3 P0DMS8 1/20 0.44
▸ ADORA2B P29275 1/20 0.44
▸ GSK3B P49841 1/20 0.44
▸ MAPK14 Q16539 1/20 0.44
▸ ALDH1A1 P00352 6/20 0.43
▸ MIF P14174 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ PDE5A O76074 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3193389 0.84 ALDH1A1 (0.60) EGFRADORA2AADORA1RAF1ADORA3
SCHEMBL8224745 0.82 MAPK14 (0.49) EGFRADORA2AADORA1RAF1ADORA3
Hydrochloric Acid SCHEMBL3197694 0.81 MAPK14 (0.48) EGFRADORA2AADORA1RAF1ADORA3
SCHEMBL5379439 0.78 MAPK14 (0.54) EGFRADORA2AADORA1RAF1ADORA3
SCHEMBL5392749 0.76 EGFR (0.56) EGFRADORA2AADORA1RAF1ADORA3
SCHEMBL5389831 0.75 EGFR (0.56) LMNAEGFRADORA2AADORA1RAF1
SCHEMBL3194040 0.75 EGFR (0.53) EGFRADORA2AADORA1RAF1ADORA3
SCHEMBL3210911 0.74 EGFR (0.44) LMNAEGFRADORA2AADORA1RAF1
SCHEMBL3187134 0.74 KMT2A (0.66) EGFRADORA2AADORA1GSK3BALDH1A1
SCHEMBL3203205 0.73 MAPK14 (0.49) EGFRADORA2AADORA1RAF1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2010-02-11 — — US disclosed
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE MEDICINOVA, INC. 2009-12-24 — — US disclosed
US-7585875-B2 Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use AVIGEN, INC. (US) 2009-09-08 — — US disclosed
EP-2038279-A2 SUBSTITUTED PYRAZOLO [1,5- ALPHA] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE Avigen, Inc. (US) 2009-03-25 — — EP disclosed
WO-2007146087-A2 SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2007-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 LMNA 3664/4885EGFR 3334/4885ADORA2A 236/4885
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 LMNA 3664/4885EGFR 3334/4885ADORA2A 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.